Physician profile
Michael Burk
NPI 1356785265
$5,250.54
in general payments reported to CMS, 2019-2025
24 companies · $16.70 in 2025
The $16.70 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $246 · 2021: $1,087 · 2022: $419 · 2023: $3,482 · 2025: $16.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $482 · Food and Beverage: $16.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $482.36 |
| Food and Beverage | $16.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,482.36 | 2023 | Ion, Da Vinci Surgical System |
| Inspire Medical Systems, INC. | $352.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $339.64 | 2020-2022 | |
| Glaxosmithkline, LLC. | $195.83 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.83 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $115.33 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $111.54 | 2021-2022 | |
| Grifols USA, LLC | $73.84 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $40.01 | 2021 | |
| Genentech USA, INC. | $39.55 | 2021-2022 | |
| Insmed, INC. | $36.67 | 2021 | |
| Gilead Sciences, INC. | $34.73 | 2021 | |
| Mylan Specialty L.P. | $31.54 | 2021 | |
| Philips North America LLC | $29.21 | 2020 | |
| United Therapeutics Corporation | $24.55 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $24.41 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.35 | 2020 | |
| Harmony Biosciences LLC | $24.31 | 2022 | |
| Genzyme Corporation | $22.92 | 2021 | |
| 3b Medical, INC. | $16.70 | 2025 | Luna |
| Astellas Pharma US INC | $16.46 | 2021 | |
| Olympus America INC. | $14.90 | 2021 | |
| Adma Biomanufacturing LLC | $14.45 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Burk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.